Bioactive peptide SEPKPIFF and preparation method and application thereof
阅读说明：本技术 一种生物活性肽sepkpiff及其制备方法和应用 (Bioactive peptide SEPKPIFF and preparation method and application thereof ) 是由 张少辉 占文静 张伯宇 于 2021-01-19 设计创作，主要内容包括：本发明涉及蛋白领域,具体涉及一种生物活性肽SEPKPIFF及其制备方法和应用,生物活性肽SEPKPIFF的氨基酸序列为Ser-Glu-Pro-Lys-Pro-Ile-Phe-Phe。经过体外免疫调节功能验证实验,证明生物活性肽SEPKPIFF具有很好的免疫调节功能。本发明的生物活性肽SEPKPIFF能够增强淋巴细胞的体外增殖能力,可有效抑制机体因氧化而引起的炎症,提高机体抵御外界病原体感染的能力,降低机体发病率,对治疗炎症引起的慢性疾病具有很大帮助,对开发具有免疫调节功能的食品、保健品和药物具有十分重要的意义。(The invention relates to the field of protein, and in particular relates to a bioactive peptide SEPKPIFF, a preparation method and application thereof. In-vitro immune regulation function verification experiments prove that the bioactive peptide SEPKPIFF has a good immune regulation function. The bioactive peptide SEPKPIFF can enhance the in-vitro proliferation capacity of lymphocytes, can effectively inhibit inflammation caused by oxidation of an organism, improves the capability of the organism for resisting infection of external pathogens, reduces the morbidity of the organism, is very helpful for treating chronic diseases caused by inflammation, and has very important significance for developing foods, health-care products and medicines with immunoregulation function.)
1. A bioactive peptide SEPKPIFF is characterized in that the amino acid sequence is Ser-Glu-Pro-Lys-Pro-Ile-Phe-Phe.
2. A polynucleotide encoding said biologically active peptide sepfpiff.
3. The method of claim 1, wherein the biologically active peptide SEPKPIFF is synthesized by genetic engineering, obtained directly from cells by isolation and purification, or prepared directly by chemical synthesis.
4. The use of the biologically active peptide, sepfpiff, according to claim 1, for the preparation of a medicament or cosmetic product with anti-inflammatory properties.
5. The use of the biologically active peptide, SEPKPIFF, according to claim 4, wherein said biologically active peptide, SEPKPIFF, is used in the manufacture of a medicament or cosmetic for inhibiting inflammation due to oxidation.
6. The use of the biologically active peptide, sepfpiff, according to claim 1, for the preparation of a food or a pharmaceutical product with immunomodulating properties.
7. The use of the biologically active peptide, SEPKPIFF, according to claim 6, in the preparation of a food or a medicament for promoting the proliferation of giant lymphocytes.
8. An anti-inflammatory product comprising the biologically active peptide SEPKPIFF of claim 1 or a derivative of said biologically active peptide SEPKPIFF; the anti-inflammatory product comprises an anti-inflammatory drug or an anti-inflammatory cosmetic; the derivatives of the biologically active peptide SEPKPIFF are meant to have the same activity or better activity than the biologically active peptide SEPKPIFF.
9. A product having an immunoregulatory function comprising the biologically active peptide sepfpiff of claim 1 or a derivative of said biologically active peptide sepfpiff; the product with immunoregulation function comprises food with immunoregulation function or medicine with immunoregulation function; the derivatives of the biologically active peptide SEPKPIFF are meant to have the same activity or better activity than the biologically active peptide SEPKPIFF.
10. The anti-inflammatory product of claim 8 or the product with immunoregulatory function of claim 9 wherein the derivative of biologically active peptide sepfpiff is a derivative of biologically active peptide obtained by modification of amino acid side chain group, amino terminus or carboxy terminus of biologically active peptide sepfpiff by hydroxylation, carboxylation, carbonylation, methylation, acetylation, phosphorylation, esterification or glycosylation.
Technical Field
The invention relates to the field of protein, in particular to a bioactive peptide SEPKPIFF, a preparation method and application thereof.
Background
Immunomodulatory peptides generally refer to small, relatively small molecular weight peptides with immunomodulatory activity. Immunomodulatory peptides are a class of bioactive peptides that were first obtained from milk following opioid peptide discovery and demonstrated their physiological activity. Jolles et al found in 1981 for the first time that a hexapeptide with an amino acid sequence Val-Glu-Pro-Ile-Pro-Tyr can be obtained by hydrolyzing human milk protein with trypsin, and in vitro experiments prove that the hexapeptide can enhance the phagocytosis of mouse abdominal cavity macrophages to sheep erythrocytes. Migliore-Samour et al found that the casein-derived hexapeptide Thr-Thr-Met-Pro-Leu-Trp was able to stimulate phagocytosis of murine peritoneal macrophages by sheep red blood cells and to enhance resistance to Klebsiella pneumoniae, with anti-inflammatory properties. Lemna hexandra et al, fed rats with synthetic mouse bone marrow macrophages and a source peptide (PGPIPN), found that phagocytosis of rat peritoneal macrophages and red blood cell-related anti-inflammatory function were significantly enhanced. Bowdis et al, in studying the immune function of the 13 amino acid peptide indolicidin derived from bovine neutrophils, found that the polypeptide indolicidin inhibits LPS-induced TNF- α production in a macrophage-like cell line.
The immunomodulatory peptides presently disclosed are generally small peptides with specific immunomodulatory activity, isolated enzymatically from proteins or synthesized chemically. However, when these small peptides are not enzymatically separated from the protein, the protein itself often has no immunomodulatory activity. It is one of the directions in the field of protein research to find bioactive peptides with specific functions from a wide variety of proteins whose amino acid sequences are known, and to study the functions of these polypeptides.
The amino acid sequence of Protein SON Protein is shown as SEQ ID NO: 2, respectively. At present, no research on related functions of polypeptide fragments of Protein SON Protein exists in the prior art.
Disclosure of Invention
The invention aims to provide a bioactive peptide SEPKPIFF, and a preparation method and application thereof.
The purpose of the invention can be realized by the following technical scheme:
in a first aspect of the invention, a biologically active peptide SEPKPIFF is provided, the amino acid sequence of which is Ser-Glu-Pro-Lys-Pro-Ile-Phe-Phe, as shown in SEQ ID NO: 1 is shown.
Preferably, the bioactive peptide is mouse spleen derived lymphocyte peptide. Specifically, the Protein SON Protein is derived from Protein SON Protein and is 2164-2171 th amino acid residue of the Protein SON Protein. The Protein SON Protein has an amino acid sequence shown as SEQ ID NO: 2, respectively.
The amino acid sequence and the corresponding nucleotide sequence of the Protein SON Protein are the existing technology, and the nucleotide fragment for coding the 2164 th to 2171 th amino acid residues of the Protein SON Protein can code the mature bioactive peptide SEPKPIFF.
Preferably, the bioactive peptide has anti-inflammatory and immunoregulatory functions.
The invention also provides a polynucleotide for coding the bioactive peptide SEPKPIFF.
In a second aspect of the present invention, there is provided a method for preparing the bioactive peptide sepfpiff, which can be artificially synthesized by genetic engineering methods, can be directly obtained from cells by separation and purification methods, and can be directly prepared by chemical synthesis.
The artificial synthesis of the biologically active peptide SEPKPIFF by genetic engineering methods is a technical solution which can be realized by a person skilled in the art, and for example, the sequence synthesis of the polypeptide can be controlled by a suitable DNA template based on DNA recombination technology.
The method for directly obtaining the cell by the separation and purification method can be as follows: based on the amino acid sequence of the given bioactive peptide SEPKPIFF, the bioactive peptide SEPKPIFF is obtained from mouse spleen-derived lymphocytes by adopting a conventional enzymolysis and purification method in biological technology.
In a third aspect of the invention, the application of the bioactive peptide SEPKPIFF in the preparation of medicines or cosmetics with anti-inflammatory functions is provided.
In particular, the bioactive peptide SEPKPIFF of the invention can be used for preparing medicaments with anti-inflammatory and/or antioxidant effects.
Further, the application of the bioactive peptide SEPKPIFF in preparing a medicament for inhibiting inflammation caused by oxidation.
In the fourth aspect of the invention, the application of the bioactive peptide SEPKPIFF in preparing food or medicines with immunoregulation function is provided.
Further, the application of the bioactive peptide SEPKPIFF in preparing food or medicines for promoting the proliferation of giant lymphocytes is provided.
In a fifth aspect of the invention, there is provided an anti-inflammatory product comprising said biologically active peptide, sepfpiff, or a derivative of said biologically active peptide, sepfpiff; the anti-inflammatory product comprises an anti-inflammatory drug or an anti-inflammatory cosmetic.
In a sixth aspect of the present invention, there is provided a product having an immunoregulatory function, comprising the biologically active peptide sepfpiff or a derivative of the biologically active peptide sepfpiff; the product with immunoregulatory function comprises food with immunoregulatory function or medicine with immunoregulatory function.
The derivatives of the biologically active peptide SEPKPIFF are meant to have the same activity or better activity than the biologically active peptide SEPKPIFF.
The derivative of the bioactive peptide SEPKPIFF refers to a bioactive peptide derivative obtained by modifying amino acid side chain groups, amino terminals or carboxyl terminals of the bioactive peptide SEPKPIFF through hydroxylation, carboxylation, carbonylation, methylation, acetylation, phosphorylation, esterification or glycosylation.
The biological active peptide SEPKPIFF has the beneficial effects that: the bioactive peptide SEPKPIFF has good anti-inflammatory activity; the bioactive peptide SEPKPIFF can enhance the in-vitro proliferation capacity of lymphocytes, effectively inhibit inflammation caused by oxidation of an organism, improve the capability of the organism for resisting infection of external pathogens, reduce the morbidity of the organism, greatly help to treat chronic diseases caused by inflammation, and has very important significance for developing foods, health-care products and medicines with immunoregulation function.
Drawings
FIG. 1: a first order mass spectrum of a fragment with a mass to charge ratio of 482.761 (m/z 482.761);
FIG. 2: a secondary mass spectrum of a fragment with a mass-to-charge ratio of 482.761 and the breakage conditions of the polypeptides az and by;
Detailed Description
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, and materials used in the examples, any methods, devices, and materials similar or equivalent to those described in the examples may be used in the practice of the invention in addition to the specific methods, devices, and materials used in the examples, in keeping with the knowledge of one skilled in the art and with the description of the invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed herein all employ techniques conventional in the art of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related arts. These techniques are well described in the literature, and may be found in particular in the study of the MOLECULAR CLONING, Sambrook et al: a LABORATORY MANUAL, Second edition, Cold Spring Harbor LABORATORY Press, 1989and Third edition, 2001; ausubel et al, Current PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; (iii) METHODS IN ENZYMOLOGY, Vol.304, Chromatin (P.M.Wassarman and A.P.Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol.119, chromatography Protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999, etc.
The invention is described in detail below with reference to the figures and specific embodiments.
EXAMPLE 1 Artificial Synthesis of an active peptide, SEPKPIFF
Synthesis of bioactive peptide
1.3 g of RINK resin (degree of substitution 0.3mmol/g) was weighed into a 150ml reactor and soaked with 50ml of Dichloromethane (DCM).
After 2.2 hours, the resin was washed with 3 resin volumes of N-Dimethylformamide (DMF) and then drained, and this was repeated four times and the resin was drained until use.
3. The Fmoc protecting group on the resin was removed by adding a quantity of 20% piperidine (piperidine/DMF: 1:4, v: v) to the reactor and shaking on a decolourising shaker for 20 min. After deprotection, the resin was washed four times with 3 resin volumes of DMF and then drained.
4. And (3) detecting a small amount of resin by a ninhydrin (ninhydrin) method (detecting A and B, respectively, and reacting at 100 ℃ for 1min), wherein the resin is colored, which indicates that the deprotection is successful.
5. Weighing a proper amount of amino acid Ser and a proper amount of 1-hydroxy-benzotriazole (HOBT) into a 50ml centrifuge tube, adding 20ml of DMF to dissolve the amino acid Ser and the 1-hydroxy-benzotriazole (HOBT), then adding 3ml of N, N Diisopropylcarbodiimide (DIC) to shake and shake for 1min, adding the solution into a reactor after the solution is clarified, and then placing the reactor into a 30 ℃ shaking table to react.
After 6.2 hours, the column was capped with a suitable amount of acetic anhydride (acetic anhydride: DIEA: DCM ═ 1:1:2, v: v: v) for half an hour, then washed four times with 3 resin volumes of DMF and drained until needed.
7. The Fmoc protecting group on the resin was removed by adding a quantity of 20% piperidine (piperidine/DMF: 1:4, v: v) to the reactor and shaking on a decolourising shaker for 20 min. After deprotection was washed four times with DMF and then drained.
8. And (3) detecting a small amount of resin by a ninhydrin (ninhydrin) method (detecting A and B, respectively, and reacting at 100 ℃ for 1min), wherein the resin is colored, which indicates that the deprotection is successful.
9. Weighing a second proper amount of amino acid and a proper amount of HOBT in a 50ml centrifuge tube, adding 25ml of DMF to dissolve the amino acid and the HOBT, adding 2.5ml of DIC to shake and shake for 1min, adding the solution into a reactor after the solution is clarified, and then placing the reactor in a shaking table at 30 ℃ to react.
After 10.1 hours, a small amount of resin is taken for detection, and the detection is carried out by an indanthrone method (two drops are respectively detected A and B, and the reaction is carried out for 1min at 100 ℃), if the resin is colorless, the reaction is complete; if the resin is colored, the condensation is not complete and the reaction is continued.
11. After the reaction was completed, the resin was washed four times with DMF and then drained, and a certain amount of 20% piperidine (piperidine/DMF ═ 1:4, v: v) was added to the reactor, and the mixture was shaken on a decolorizing shaker for 20min to remove the Fmoc-protecting group from the resin. After the protection is removed, washing with DMF for four times, and then draining to detect whether the protection is removed.
12. The amino acids Ser, Glu, Pro, Lys, Pro, Ile, Phe are sequentially grafted according to steps 9-11.
13. After the last amino acid had been grafted, the protection was removed, washed four times with DMF and the resin was drained with methanol. The biologically active peptide was then cleaved from the resin using 95 cleavage medium (trifluoroacetic acid: 1,2 ethanedithiol: 3, isopropylsilane: water: 95:2:2:1, v: v: v) (10 ml of cleavage medium per gram of resin) and centrifuged four times with glacial ethyl ether (cleavage medium: ethyl ether: 1:9, v: v).
Thus, the bioactive peptide SEPKPIFF is artificially synthesized.
Confirmation of biologically active peptides
1) UPLC analysis
UPLC conditions were as follows:
the instrument comprises the following steps: waters ACQUITY UPLC ultra-high performance liquid phase, electrospray, quadrupole and time-of-flight mass spectrometer
Specification of chromatographic column: BEH C18 chromatographic column
Flow rate: 0.4mL/min
Temperature: 50 deg.C
Ultraviolet detection wavelength: 210nm
Sample introduction amount: 2 μ L
Gradient conditions: solution A: water containing 0.1% formic acid (v/v), liquid B: acetonitrile containing 0.1% formic acid (v/v)
2) Mass spectrometric analysis
The mass spectrometry conditions were as follows:
ion mode: ES +
Mass range (m/z): 100. 1000A
Capillary voltage (Capillary) (kV): 3.0
Sampling cone (V): 35.0
Ion source temperature (. degree. C.): 115
Desolvation temperature (. degree. C.): 350
Desolventizing gas stream (L/hr): 700.0
Collision energy (eV): 4.0
Scan time (sec): 0.25
Inner scan time (sec): 0.02
According to the analysis method, chromatographic analysis and mass spectrum analysis are carried out on the bioactive peptide SEPKPIFF by using ultra-high performance liquid phase, electrospray, a quadrupole and time-of-flight mass spectrum. The primary mass spectrum of the bioactive peptide SEPKPIFF is shown in figure 1, the secondary mass spectrum of the extracted peak and the az and by fracture conditions are shown in figure 2, the mass-to-charge ratio of the bioactive peptide of the peak is 482.761, and the retention time is 44.63 min.
3) Results
As can be seen from fig. 2, the fragment sequences of mass-to-charge ratio 482.761 were calculated by Mascot software analysis based on az and by cleavage, and were Ser, Glu, Pro, Lys, Pro, Ile, Phe (sepfpiff), and were represented as SEQ ID NO: 1. the fragment corresponds to residue sequences of 2164-2171 th sites of Protein SON Protein, the GenBank number of the amino acid sequence of the Protein SON Protein is AC131691, and the sequence is shown in SEQ ID NO: 2.
example 2 immunological Activity assay of bioactive peptides
Experiment of biological active peptide SEPKPIFF on immune cell factor in serum
1. Experimental reagents and instruments:
reagent: experimental animal ICR mouse (male 5 weeks old), shanghai city experimental animal center; d-gal, national pharmaceutical group chemical reagents, Inc.; paraformaldehyde, chemical reagents of the national drug group, ltd; sodium chloride, national pharmaceutical group chemical reagents ltd; the mouse spleen lymphocyte-derived bioactive peptide SEPKPIFF obtained in example 1; BCA protein kit, Nanjing Kaikyi Biotech Co., Ltd; ELISA cytokine Rapid kits (TNF-. alpha.and IL-6), Wuhan Dr bioengineering, Inc.
The instrument equipment comprises: model CM-230 Mohr super Water, Shanghai Mole scientific instruments, Inc.; millipore Milllex GP0.22 μm membrane filter, Millipore USA; GL-22M high-speed refrigerated centrifuge, Shanghai Luxiang apparatus centrifuge instruments Inc.
2. The experimental method comprises the following steps:
(1) model for animal aging
After one week of adaptive ICR mouse feeding, 4 groups of 6 mice were divided. Group 1 was a low dose intragastric group, mice were injected subcutaneously in the neck and back at a dose of 500mg/kg daily with D-gal, and intragastric bioactive peptide SEPKPIFF at a dose of 1 mg/day; group 2 was a high dose gavage group, mice were injected subcutaneously in the neck and back at a dose of 500mg/kg daily and the bioactive peptide SEPKPIFF was gavage at a daily dose of 3 mg/mouse; group 3 was blank, mice grew normally; group 4 was an animal model group, and mice were injected subcutaneously into the neck and back with D-gal at a dose of 500mg/kg daily, and gavage with 0.9% normal saline; the injection period of the D-gal and the gavage period of the bioactive peptide are both 42 days. The bedding is replaced every 3 days and the feed and distilled water supply is ensured. The weight of the mice was weighed once every five days, D-gal injection was prepared according to the weight of the mice, and the D-gal injection was filtered through a 0.22 μm syringe filter to ensure sterility.
(2) Obtaining animal viscera and serum
After the experiment period is finished, blood of the mouse is obtained by an eyeball-picking blood-taking method, the mouse is killed by breaking the neck after the blood is obtained, then the body of the mouse is placed on a low-temperature ice box, the blood of the mouse is stood for 1 hour at room temperature, and then is centrifuged for 15min at 3000g, and serum is separated. The serum was stored in a freezer at-80 ℃ for testing. All procedures in the procedure of treating the experimental animals followed the guidance comments on the animals being treated in good care published by the department of scientific technology in 2006. The spleen of the mouse is directly soaked in a prepared 4% paraformaldehyde solution to fix the shape. The paraformaldehyde powder is relatively insoluble, and a trace amount of sodium bicarbonate can be added to adjust the pH value to be alkaline so as to aid dissolution. The preparation of the paraformaldehyde solution needs to be completed in a fume hood.
(3) Sample detection
According to the instruction of the kit, firstly, a standard curve is drawn, standard powder is prepared into a solution of 1000pg/mL by using a standard diluent, and then the solution is continuously diluted into different concentrations of 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL, 31.3pg/mL, 15.6pg/mL and the like. Each concentration gradient solution was pipetted at 100. mu.L in an antibody-coated microplate. And (3) sucking 100 mu L of mouse serum sample, and adding the mouse serum sample into the same enzyme label plate (if the serum sample is insufficient, the mouse serum sample can be diluted properly and then needs to be converted proportionally when being detected and calculated). The plate was covered and incubated at 37 ℃ for 90 min. After the reaction is finished, carefully throwing off the liquid in the ELISA plate, placing the ELISA plate on absorbent paper, carefully beating the absorbent paper, and removing the redundant liquid. Adding preheated biotin anti-antibody working solution into each hole of the ELISA plate according to 100 mu L of each hole, and reacting for 60min at 37 ℃. After the reaction was completed, the reaction solution was washed 3 times with 0.01M PBS, 100. mu.L of PBS was added to each well, and the solution was removed after soaking for 1min, and the reaction was repeated 3 times. The preheated ABC working solution is added into each hole according to the volume of 0.1ml in turn, and the reaction is carried out for 30min at the temperature of 37 ℃. After the reaction, the reaction mixture was washed with 0.01M PBS for 5 times, and soaked for about 1min each time. Adding TMB color development solution which is balanced at 37 ℃ for 30min in turn according to 90 mu L per hole, and reacting for 8-12min at 37 ℃ in a dark place. TMB stop solution was added in an amount of 0.1ml per well in this order, and the color blue was immediately changed to yellow, and the OD value was measured at 450nm using a microplate reader. The standard protein of the cell factor is serially diluted in known concentration, an OD value is measured, a standard curve is drawn, and the content of the cell factor in the specimen can be calculated according to the standard curve.
3. Experimental results and analysis:
TABLE 1 Change in cytokines in serum of mice in each group
From Table 1, it can be found that the IL-6 and TNF-alpha contents in the model group mice in the experiment are 184.833 + -20.48 pg/mL and 3.894 + -0.38 pg/mL respectively, which show significant increase (P <0.01) compared with the normal group, so that the mice in the model group are considered to have symptoms of aging inflammation at the level of cell factor due to continuous injection of the aging-causing factor, and the IL-6 and TNF-alpha contents in the serum of the mice in the bioactive peptide gavage group are effectively controlled. According to the experimental result of the cell factors, the secretion levels of serum inflammatory cell factors IL-6 and TNF-alpha of the mice in the bioactive peptide gavage group are lower than those of the mice in the animal model group, and the oxidation damage of the mice caused by free radical attack and peroxidation product accumulation can be inhibited to a certain degree from the perspective of the oxidation damage; from the viewpoint of inflammation, the inflammation caused by oxidation of the mice is effectively inhibited; from the aging point of view, a series of senile diseases of mice caused by aging caused by long-term injection of D-gal are likely to be controlled. Therefore, the SEPKPIFF can be determined to be capable of effectively inhibiting the inflammation caused by the oxidation of the mouse, has a certain immunoregulation effect, and can be used for research and development of health care products.
Second, in vitro lymphocyte proliferation capacity experiment (MTT method) of bioactive peptide SEPKPIFF
1. Experimental materials and instruments:
reagents and materials: experimental animals balb/c mice (male 6-8 weeks old, animal experiment center of Shanghai university of transportation, college of agriculture and biology); the mouse spleen lymphocyte-derived bioactive peptide SEPKPIFF obtained in example 1; mouse lymphocyte extract (ex solibao); RPMI1640 medium (purchased from GIBCO); 3- (4, 5-Dimethylthiazol-2) -2, 5-diphenyltetrazolium bromide salt (MTT, available from Amresco, Inc.); concanavalin (ConA, available from Sigma); bovine serum albumin (BSA, available from Genebase); pepsin (available from Sigma); pancreatin (Corolase PP, from AB).
The instrument equipment comprises: LRH-250F Biochemical incubator, Shanghai Hengshi Co., Ltd; GL-22M high speed refrigerated centrifuge, shanghai luxiang instrument centrifuge instruments ltd; hera cell 150 CO2Incubator, Heraeus corporation; dragon Wellscan MK3 microplate reader, Labsystems Inc.; ALPHA 1-2-LD vacuum freeze drier, Christ company; ultra performance liquid chromatography-quadrupole time-of-flight mass spectrometer, waters corporation.
2. The experimental method comprises the following steps:
taking mouse spleen under aseptic condition, extracting mouse lymphocyte with lymphocyte extract, and performing primary culture. The cell density was adjusted to 2.5X 10 with complete RPMI1640 medium6one/mL. To a 96-well cell culture plate were added in sequence: 100 μ L mouse lymphocyte suspension, 100 μ L RPMI1640 complete medium, 20 μ L concanavalin, 100 μ L bioactive peptide sample. In addition, a blank control group (PBS with pH7.2-7.4 and 3 mol/L) and a negative control group (500 mu g/mL BSA) are arranged, and the research shows that the blank control group has no influence on the in vitro lymphocyte proliferation. Each set of 3 replicates. At 5% CO2Culturing at 37 deg.C for 68h, adding 20 μ L MTT into each well under aseptic condition, culturing for 4h, carefully removing supernatant, adding 100 μ L dimethyl sulfoxide into each well, incubating at 37 deg.C for 10min, shaking, and measuring absorbance at 570nm with microplate reader.
The in vitro lymphocyte proliferation capacity is expressed by a stimulation index and is calculated as follows:
in the formula: a. the1Absorbance at 570nm for the blank; a. the2Absorbance at 570nm for the negative control, A3The absorbance at 570nm for the experimental group.
3. Experimental results and analysis:
TABLE 2 Effect of the bioactive peptide SEPKPIFF on lymphocyte proliferation in vitro
Experiment grouping
Stimulation index SI
BSA
1
SEPKPIFF
1.2031±0.0734*
Note: the number marked as significant difference (P <0.05) compared to the negative control.
The results are shown in Table 2. As can be seen from Table 2, the stimulation index of the bioactive peptide SEPKPIFF is greater than that of BSA under the condition that the mass concentration of the bioactive peptide SEPKPIFF is 150 mug/mL, which indicates that SEPKPIFF can stimulate the proliferation of mouse lymphocytes in vitro to a certain extent. And the stimulation index of SEPKPIFF reaches 1.2031, which is obviously different from that of a negative control group (P < 0.05). Therefore, the biological active peptide SEPKPIFF can be considered to have the capacity of remarkably promoting the mouse lymphocyte proliferation, can be used as a substance with immunoregulation activity to be added into a health-care product, and can improve the immunity of a human body.
The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
Sequence listing
<110> Zhejiang ghui peptide Life health science and technology Limited
<120> bioactive peptide SEPKPIFF and preparation method and application thereof
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Ser Glu Pro Lys Pro Ile Phe Phe
1 5
<210> 2
<211> 2444
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Met Ala Ala Asp Ile Glu Gln Val Phe Arg Ser Phe Val Val Ser Lys
1 5 10 15
Phe Arg Glu Ile Gln Gln Glu Leu Ser Ser Gly Arg Ser Glu Gly Gln
20 25 30
Leu Asn Gly Glu Thr Asn Pro Pro Ile Glu Gly Asn Gln Ala Gly Asp
35 40 45
Thr Ala Ala Ser Ala Arg Ser Leu Pro Asn Glu Glu Ile Val Gln Lys
50 55 60
Ile Glu Glu Val Leu Ser Gly Val Leu Asp Thr Glu Leu Arg Tyr Lys
65 70 75 80
Pro Asp Leu Lys Glu Ala Ser Arg Lys Ser Arg Cys Val Ser Val Gln
85 90 95
Thr Asp Pro Thr Asp Glu Val Pro Thr Lys Lys Ser Lys Lys His Lys
100 105 110
Lys His Lys Asn Lys Lys Lys Lys Lys Lys Lys Glu Lys Glu Lys Lys
115 120 125
Tyr Lys Arg Gln Pro Glu Glu Ser Glu Ser Lys Leu Lys Ser His His
130 135 140
Asp Gly Asn Leu Glu Ser Asp Ser Phe Leu Lys Phe Asp Ser Glu Pro
145 150 155 160
Ser Ala Ala Ala Leu Glu His Pro Val Arg Ala Phe Gly Leu Ser Glu
165 170 175
Ala Ser Glu Thr Ala Leu Val Leu Glu Pro Pro Val Val Ser Met Glu
180 185 190
Val Gln Glu Ser His Val Leu Glu Thr Leu Lys Pro Ala Thr Lys Ala
195 200 205
Ala Glu Leu Ser Val Val Ser Thr Ser Val Ile Ser Glu Gln Ser Glu
210 215 220
Gln Pro Met Pro Gly Met Leu Glu Pro Ser Met Thr Lys Ile Leu Asp
225 230 235 240
Ser Phe Thr Ala Ala Pro Val Pro Met Ser Thr Ala Ala Leu Lys Ser
245 250 255
Pro Glu Pro Val Val Thr Met Ser Val Glu Tyr Gln Lys Ser Val Leu
260 265 270
Lys Ser Leu Glu Thr Met Pro Pro Glu Thr Ser Lys Thr Thr Leu Val
275 280 285
Glu Leu Pro Ile Ala Lys Val Val Glu Pro Ser Glu Thr Leu Thr Ile
290 295 300
Val Ser Glu Thr Pro Thr Glu Val His Pro Glu Pro Ser Pro Ser Thr
305 310 315 320
Met Asp Phe Pro Glu Ser Ser Thr Thr Asp Val Gln Arg Leu Pro Glu
325 330 335
Gln Pro Val Glu Ala Pro Ser Glu Ile Ala Asp Ser Ser Met Thr Arg
340 345 350
Pro Gln Glu Ser Leu Glu Leu Pro Lys Thr Thr Ala Val Glu Leu Gln
355 360 365
Glu Ser Thr Val Ala Ser Ala Leu Glu Leu Pro Gly Pro Pro Ala Thr
370 375 380
Ser Ile Leu Glu Leu Gln Gly Pro Pro Val Thr Pro Val Pro Glu Leu
385 390 395 400
Pro Gly Pro Ser Ala Thr Pro Val Pro Glu Leu Ser Gly Pro Leu Ser
405 410 415
Thr Pro Val Pro Glu Leu Pro Gly Pro Pro Ala Thr Val Val Pro Glu
420 425 430
Leu Pro Gly Pro Ser Val Thr Pro Val Pro Gln Leu Ser Gln Glu Leu
435 440 445
Pro Gly Pro Pro Ala Pro Ser Met Gly Leu Glu Pro Pro Gln Glu Val
450 455 460
Pro Glu Pro Pro Val Met Ala Gln Glu Leu Ser Gly Val Pro Ala Val
465 470 475 480
Ser Ala Ala Ile Glu Leu Thr Gly Gln Pro Ala Val Thr Val Ala Met
485 490 495
Glu Leu Thr Glu Gln Pro Val Thr Thr Thr Glu Phe Glu Gln Pro Val
500 505 510
Ala Met Thr Thr Val Glu His Pro Gly His Pro Glu Val Thr Thr Ala
515 520 525
Thr Gly Leu Leu Gly Gln Pro Glu Ala Ala Met Val Leu Glu Leu Pro
530 535 540
Gly Gln Pro Val Ala Thr Thr Ala Leu Glu Leu Ser Gly Gln Pro Ser
545 550 555 560
Val Thr Gly Val Pro Glu Leu Ser Gly Leu Pro Ser Ala Thr Arg Ala
565 570 575
Leu Glu Leu Ser Gly Gln Ser Val Ala Thr Gly Ala Leu Glu Leu Pro
580 585 590
Gly Gln Leu Met Ala Thr Gly Ala Leu Glu Phe Ser Gly Gln Ser Gly
595 600 605
Ala Ala Gly Ala Leu Glu Leu Leu Gly Gln Pro Leu Ala Thr Gly Val
610 615 620
Leu Glu Leu Pro Gly Gln Pro Gly Ala Pro Glu Leu Pro Gly Gln Pro
625 630 635 640
Val Ala Thr Val Ala Leu Glu Ile Ser Val Gln Ser Val Val Thr Thr
645 650 655
Ser Glu Leu Ser Thr Met Thr Val Ser Gln Ser Leu Glu Val Pro Ser
660 665 670
Thr Thr Ala Leu Glu Ser Tyr Asn Thr Val Ala Gln Glu Leu Pro Thr
675 680 685
Thr Leu Val Gly Glu Thr Ser Val Thr Val Gly Val Asp Pro Leu Met
690 695 700
Ala Gln Glu Ser His Met Leu Ala Ser Asn Thr Met Glu Thr His Met
705 710 715 720
Leu Ala Ser Asn Thr Met Asp Ser Gln Met Leu Ala Ser Asn Thr Met
725 730 735
Asp Ser Gln Met Leu Ala Ser Asn Thr Met Asp Ser Gln Met Leu Ala
740 745 750
Ser Ser Thr Met Asp Ser Gln Met Leu Ala Ser Ser Thr Met Asp Ser
755 760 765
Gln Met Leu Ala Thr Ser Thr Met Asp Ser Gln Met Leu Ala Thr Ser
770 775 780
Ser Met Asp Ser Gln Met Leu Ala Thr Ser Ser Met Asp Ser Gln Met
785 790 795 800
Leu Ala Thr Ser Ser Met Asp Ser Gln Met Leu Ala Thr Ser Ser Met
805 810 815
Asp Ser Gln Met Leu Ala Thr Ser Ser Met Asp Ser Gln Met Leu Ala
820 825 830
Thr Ser Ser Met Asp Ser Gln Met Leu Ala Thr Ser Ser Met Asp Ser
835 840 845
Gln Met Leu Ala Thr Ser Ser Met Asp Ser Gln Met Leu Ala Ser Gly
850 855 860
Ala Met Asp Ser Gln Met Leu Ala Ser Gly Thr Met Asp Ala Gln Met
865 870 875 880
Leu Ala Ser Gly Thr Met Asp Ala Gln Met Leu Ala Ser Ser Thr Gln
885 890 895
Asp Ser Ala Met Met Gly Ser Lys Ser Pro Asp Pro Tyr Arg Leu Ala
900 905 910
Gln Asp Pro Tyr Arg Leu Ala Gln Asp Pro Tyr Arg Leu Gly His Asp
915 920 925
Pro Tyr Arg Leu Gly His Asp Ala Tyr Arg Leu Gly Gln Asp Pro Tyr
930 935 940
Arg Leu Gly His Asp Pro Tyr Arg Leu Thr Pro Asp Pro Tyr Arg Val
945 950 955 960
Ser Pro Arg Pro Tyr Arg Ile Ala Pro Arg Ser Tyr Arg Ile Ala Pro
965 970 975
Arg Pro Tyr Arg Leu Ala Pro Arg Pro Leu Met Leu Ala Ser Arg Arg
980 985 990
Ser Met Met Met Ser Tyr Ala Ala Glu Arg Ser Met Met Ser Ser Tyr
995 1000 1005
Glu Arg Ser Met Met Ser Tyr Glu Arg Ser Met Met Ser Pro Met Ala
1010 1015 1020
Glu Arg Ser Met Met Ser Ala Tyr Glu Arg Ser Met Met Ser Ala Tyr
1025 1030 1035 1040
Glu Arg Ser Met Met Ser Pro Met Ala Glu Arg Ser Met Met Ser Ala
1045 1050 1055
Tyr Glu Arg Ser Met Met Ser Ala Tyr Glu Arg Ser Met Met Ser Pro
1060 1065 1070
Met Ala Asp Arg Ser Met Met Ser Met Gly Ala Asp Arg Ser Met Met
1075 1080 1085
Ser Ser Tyr Ser Ala Ala Asp Arg Ser Met Met Ser Ser Tyr Ser Ala
1090 1095 1100
Ala Asp Arg Ser Met Met Ser Ser Tyr Thr Asp Arg Ser Met Met Ser
1105 1110 1115 1120
Met Ala Ala Asp Ser Tyr Thr Asp Ser Tyr Thr Asp Ser Tyr Thr Glu
1125 1130 1135
Ala Tyr Met Val Pro Pro Leu Pro Pro Glu Glu Pro Pro Thr Met Pro
1140 1145 1150
Pro Leu Pro Pro Glu Glu Pro Pro Met Thr Pro Pro Leu Pro Pro Glu
1155 1160 1165
Glu Pro Pro Glu Gly Pro Ala Leu Ser Thr Glu Gln Ser Ala Leu Thr
1170 1175 1180
Ala Asp Asn Thr Trp Ser Thr Glu Val Thr Leu Ser Thr Gly Glu Ser
1185 1190 1195 1200
Leu Ser Gln Pro Glu Pro Pro Val Ser Gln Ser Glu Ile Ser Glu Pro
1205 1210 1215
Met Ala Val Pro Ala Asn Tyr Ser Met Ser Glu Ser Glu Thr Ser Met
1220 1225 1230
Leu Ala Ser Glu Ala Val Met Thr Val Pro Glu Pro Ala Arg Glu Pro
1235 1240 1245
Glu Ser Ser Val Thr Ser Ala Pro Val Glu Ser Ala Val Val Ala Glu
1250 1255 1260
His Glu Met Val Pro Glu Arg Pro Met Thr Tyr Met Val Ser Glu Thr
1265 1270 1275 1280
Thr Met Ser Val Glu Pro Ala Val Leu Thr Ser Glu Ala Ser Val Ile
1285 1290 1295
Ser Glu Thr Ser Glu Thr Tyr Asp Ser Met Arg Pro Ser Gly His Ala
1300 1305 1310
Ile Ser Glu Val Thr Met Ser Leu Leu Glu Pro Ala Val Thr Ile Ser
1315 1320 1325
Gln Pro Ala Glu Asn Ser Leu Glu Leu Pro Ser Met Thr Val Pro Ala
1330 1335 1340
Pro Ser Thr Met Thr Thr Thr Glu Ser Pro Val Val Ala Val Thr Glu
1345 1350 1355 1360
Ile Pro Pro Val Ala Val Pro Glu Pro Pro Ile Met Ala Val Pro Glu
1365 1370 1375
Leu Pro Thr Met Ala Val Val Lys Thr Pro Ala Val Ala Val Pro Glu
1380 1385 1390
Pro Leu Val Ala Ala Pro Glu Pro Pro Thr Met Ala Thr Pro Glu Leu
1395 1400 1405
Cys Ser Leu Ser Val Ser Glu Pro Pro Val Ala Val Ser Glu Leu Pro
1410 1415 1420
Ala Leu Ala Asp Pro Glu His Ala Ile Thr Ala Val Ser Gly Val Ser
1425 1430 1435 1440
Ser Leu Glu Pro Ser Val Pro Ile Leu Glu Pro Ala Val Ser Val Leu
1445 1450 1455
Gln Pro Val Met Ile Val Ser Glu Pro Ser Val Pro Val Gln Glu Pro
1460 1465 1470
Thr Val Ala Val Ser Glu Pro Ala Val Ile Val Ser Glu His Thr Gln
1475 1480 1485
Ile Thr Ser Pro Glu Met Ala Val Glu Ser Ser Pro Val Ile Val Asp
1490 1495 1500
Ser Ser Val Met Ser Ser Gln Ile Met Lys Gly Met Asn Leu Leu Gly
1505 1510 1515 1520
Gly Asp Glu Asn Leu Gly Pro Glu Val Gly Met Gln Glu Thr Leu Leu
1525 1530 1535
His Pro Gly Glu Glu Pro Arg Asp Gly Gly His Leu Lys Ser Asp Leu
1540 1545 1550
Tyr Glu Asn Glu Tyr Asp Arg Asn Ala Asp Leu Thr Val Asn Ser His
1555 1560 1565
Leu Ile Val Lys Asp Ala Glu His Asn Thr Val Cys Ala Thr Thr Val
1570 1575 1580
Gly Pro Val Gly Glu Ala Ser Glu Glu Lys Ile Leu Pro Ile Ser Glu
1585 1590 1595 1600
Thr Lys Glu Ile Thr Glu Leu Ala Thr Cys Ala Ala Val Ser Glu Ala
1605 1610 1615
Asp Ile Gly Arg Ser Leu Ser Ser Gln Leu Ala Leu Glu Leu Asp Thr
1620 1625 1630
Val Gly Thr Ser Lys Gly Phe Glu Phe Val Thr Ala Ser Ala Leu Ile
1635 1640 1645
Ser Glu Ser Lys Tyr Asp Val Glu Val Ser Val Thr Thr Gln Asp Thr
1650 1655 1660
Glu His Asp Met Val Ile Ser Thr Ser Pro Ser Gly Gly Ser Glu Ala
1665 1670 1675 1680
Asp Ile Glu Gly Pro Leu Pro Ala Lys Asp Ile His Leu Asp Leu Pro
1685 1690 1695
Ser Thr Asn Phe Val Cys Lys Asp Val Glu Asp Ser Leu Pro Ile Lys
1700 1705 1710
Glu Ser Ala Gln Ala Val Ala Val Ala Leu Ser Pro Lys Glu Ser Ser
1715 1720 1725
Glu Asp Thr Glu Val Pro Leu Pro Asn Lys Glu Ile Val Pro Glu Ser
1730 1735 1740
Gly Tyr Ser Ala Ser Ile Asp Glu Ile Asn Glu Ala Asp Leu Val Arg
1745 1750 1755 1760
Pro Leu Leu Pro Lys Asp Met Glu Arg Leu Thr Ser Leu Arg Ala Gly
1765 1770 1775
Ile Glu Gly Pro Leu Leu Ala Ser Glu Val Glu Arg Asp Lys Ser Ala
1780 1785 1790
Ala Ser Pro Val Val Ile Ser Ile Pro Glu Arg Ala Ser Glu Ser Ser
1795 1800 1805
Ser Glu Glu Lys Asp Asp Tyr Glu Ile Phe Val Lys Val Lys Asp Thr
1810 1815 1820
His Glu Lys Ser Lys Lys Asn Lys Asn Arg Asp Lys Gly Glu Lys Glu
1825 1830 1835 1840
Lys Lys Arg Asp Ser Ser Leu Arg Ser Arg Ser Lys Arg Ser Lys Ser
1845 1850 1855
Ser Glu His Lys Ser Arg Lys Arg Thr Ser Glu Ser Arg Ser Arg Ala
1860 1865 1870
Arg Lys Arg Ser Ser Lys Ser Lys Ser His Arg Ser Gln Thr Arg Ser
1875 1880 1885
Arg Ser Arg Ser Arg Arg Arg Arg Arg Ser Ser Arg Ser Arg Ser Lys
1890 1895 1900
Ser Arg Gly Arg Arg Ser Val Ser Lys Glu Lys Arg Lys Arg Ser Pro
1905 1910 1915 1920
Lys His Arg Ser Lys Ser Arg Glu Arg Lys Arg Lys Arg Ser Ser Ser
1925 1930 1935
Arg Asp Asn Arg Lys Ala Ala Arg Ala Arg Ser Arg Thr Pro Ser Arg
1940 1945 1950
Arg Ser Arg Ser His Thr Pro Ser Arg Arg Arg Arg Ser Arg Ser Val
1955 1960 1965
Gly Arg Arg Arg Ser Phe Ser Ile Ser Pro Ser Arg Arg Ser Arg Thr
1970 1975 1980
Pro Ser Arg Arg Ser Arg Thr Pro Ser Arg Arg Ser Arg Thr Pro Ser
1985 1990 1995 2000
Arg Arg Ser Arg Thr Pro Ser Arg Arg Ser Arg Thr Pro Ser Arg Arg
2005 2010 2015
Arg Arg Ser Arg Ser Ala Val Arg Arg Arg Ser Phe Ser Ile Ser Pro
2020 2025 2030
Val Arg Leu Arg Arg Ser Arg Thr Pro Leu Arg Arg Arg Phe Ser Arg
2035 2040 2045
Ser Pro Ile Arg Arg Lys Arg Ser Arg Ser Ser Glu Arg Gly Arg Ser
2050 2055 2060
Pro Lys Arg Leu Thr Asp Leu Asp Lys Ala Gln Leu Leu Glu Ile Ala
2065 2070 2075 2080
Lys Ala Asn Ala Ala Ala Met Cys Ala Lys Ala Gly Val Pro Leu Pro
2085 2090 2095
Pro Asn Leu Lys Pro Ala Pro Pro Pro Thr Ile Glu Glu Lys Val Ala
2100 2105 2110
Lys Lys Ser Gly Gly Ala Thr Ile Glu Glu Leu Thr Glu Lys Cys Lys
2115 2120 2125
Gln Ile Ala Gln Ser Lys Glu Asp Asp Asp Val Ile Val Asn Lys Pro
2130 2135 2140
His Val Ser Asp Glu Glu Glu Glu Glu Pro Pro Phe Tyr His His Pro
2145 2150 2155 2160
Phe Lys Leu Ser Glu Pro Lys Pro Ile Phe Phe Asn Leu Asn Ile Ala
2165 2170 2175
Ala Ala Lys Pro Thr Pro Pro Lys Ser Gln Val Thr Leu Thr Lys Glu
2180 2185 2190
Phe Pro Val Ser Ser Gly Ser Gln His Arg Lys Lys Glu Ala Asp Ser
2195 2200 2205
Val Tyr Gly Glu Trp Val Pro Val Glu Lys Asn Gly Glu Glu Ser Lys
2210 2215 2220
Asp Asp Asp Asn Val Phe Ser Ser Ser Leu Pro Ser Glu Pro Val Asp
2225 2230 2235 2240
Ile Ser Thr Ala Met Ser Glu Arg Ala Leu Ala Gln Lys Arg Leu Ser
2245 2250 2255
Glu Asn Ala Phe Asp Leu Glu Ala Met Ser Met Leu Asn Arg Ala Gln
2260 2265 2270
Glu Arg Ile Asp Ala Trp Ala Gln Leu Asn Ser Ile Pro Gly Gln Phe
2275 2280 2285
Thr Gly Ser Thr Gly Val Gln Val Leu Thr Gln Glu Gln Leu Ala Asn
2290 2295 2300
Thr Gly Ala Gln Ala Trp Ile Lys Lys Asp Gln Phe Leu Arg Ala Ala
2305 2310 2315 2320
Pro Val Thr Gly Gly Met Gly Ala Val Leu Met Arg Lys Met Gly Trp
2325 2330 2335
Arg Glu Gly Glu Gly Leu Gly Lys Asn Lys Glu Gly Asn Lys Glu Pro
2340 2345 2350
Ile Leu Val Asp Phe Lys Thr Asp Arg Lys Gly Leu Val Ala Val Gly
2355 2360 2365
Glu Arg Ala Gln Lys Arg Ser Gly Asn Phe Ser Ala Ala Met Lys Asp
2370 2375 2380
Leu Ser Gly Lys His Pro Val Ser Ala Leu Met Glu Ile Cys Asn Lys
2385 2390 2395 2400
Arg Arg Trp Gln Pro Pro Glu Phe Leu Leu Val His Asp Ser Gly Pro
2405 2410 2415
Asp His Arg Lys His Phe Leu Phe Arg Val Leu Arg Asn Gly Ser Pro
2420 2425 2430
Tyr Gln Pro Asn Cys Met Phe Phe Leu Asn Arg Tyr
2435 2440